Product Name: HER2 CISH pharmDx Kit Catalog/Model number: SK109, lot 20000910 Product Usage: For in vitro diagnostic use. HER2 CISH pharmDx Kit is intended for dual-color chromogenic visualization of signals achieved with directly labeled in situ hybridization probes targeting the HER2 gene and centromeric region of chromosome 17. The kit is designed to quantitatively determine HER2 gene status in formalin-fixed, paraffin-embedded breast cancer tissue specimens. Red and blue chromogenic signals are generated on the same tissue section for evaluation under bright field microscopy. The CISH procedure is automated using Dako Autostainer instruments. HER2 CISH pharmDx Kit is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered. Results from the HER2 CISH pharmDx Kit are intended for use as an adjunct to the clinicopathologic information currently used for estimating prognosis in stage II, node-positive breast cancer patients.
Published March 5, 2014 · Recall initiated: January 21, 2014
Summary
FDA records medical device Class II recall Z-1093-2014, published March 5, 2014 and initiated January 21, 2014. Recalling firm: Dako North America Inc.; Status: Terminated; Reported quantity: 49; Lot: Catalog/Model number: SK109, lot 20000910. Shelf Life: 10 months when stored at 2-8 ¿C. Expiration Date: 2014 June 30. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Dako has initiated a recall of HER2 CISH pharmDxTM Kit because weak red signals have been observed.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Dako North America Inc.
- Distributor
- Worldwide Distribution - USA Nationwide and in the country of Chile.
- Lot
- Catalog/Model number: SK109, lot 20000910. Shelf Life: 10 months when stored at 2-8 ¿C. Expiration Date: 2014 June 30.
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDADako Autostainer Link 48 with software version Dako Link 4.0.3, Model No. AS480 Product Usage: For in vitroOctober 1, 2014
- FDA00434811113, REF I4348-111-13 Zimmer Trabecular Metal Shoulder Humeral Stem 48 Degrees 11 mm Stem Diameter 130March 5, 2014
- FDANovaSure Impedance Controlled Endometrial Ablation System Radiofrequency Controller, Model Number: 71978-001March 5, 2014
- FDAThe FOCUS is a microprocessor controlled intra-oral x-ray unit with a Load Matching Frequency (LMF) DCMarch 5, 2014
- FDACSI, Diamondback 360 Coronary Orbital Atherectomy System, Part Number 70058-02, Model Number DBEC-125 ProductMarch 5, 2014
- FDAPT Link Waterbath, Model#PT100. Lab Vision PT Module Plus provides an automated standarized alternative toNovember 21, 2012
Questions about this recall
Was Product Name: HER2 CISH pharmDx Kit Catalog/Model number: SK109, lot 20000910 Product Usage: For in vitro diagnostic use. HER2 CISH pharmDx Kit is intended for dual-color chromogenic visualization of signals achieved with directly labeled in situ hybridization probes targeting the HER2 gene and centromeric region of chromosome 17. The kit is designed to quantitatively determine HER2 gene status in formalin-fixed, paraffin-embedded breast cancer tissue specimens. Red and blue chromogenic signals are generated on the same tissue section for evaluation under bright field microscopy. The CISH procedure is automated using Dako Autostainer instruments. HER2 CISH pharmDx Kit is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered. Results from the HER2 CISH pharmDx Kit are intended for use as an adjunct to the clinicopathologic information currently used for estimating prognosis in stage II, node-positive breast cancer patients. recalled?
Yes. FDA published recall Z-1093-2014 on March 5, 2014. Reported hazard: Dako has initiated a recall of HER2 CISH pharmDxTM Kit because weak red signals have been observed.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail